Logo image of NGNE

NEUROGENE INC (NGNE) Stock Fundamental Analysis

NASDAQ:NGNE - Nasdaq - US64135M1053 - Common Stock - Currency: USD

17.36  +0.05 (+0.29%)

After market: 17.36 0 (0%)

Fundamental Rating

2

NGNE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of NGNE is average, but there are quite some concerns on its profitability. NGNE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NGNE has reported negative net income.
NGNE had a negative operating cash flow in the past year.
NGNE had negative earnings in each of the past 5 years.
NGNE had a negative operating cash flow in each of the past 5 years.
NGNE Yearly Net Income VS EBIT VS OCF VS FCFNGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -43.34%, NGNE is in line with its industry, outperforming 52.22% of the companies in the same industry.
The Return On Equity of NGNE (-51.76%) is better than 64.48% of its industry peers.
Industry RankSector Rank
ROA -43.34%
ROE -51.76%
ROIC N/A
ROA(3y)-34.38%
ROA(5y)-33.24%
ROE(3y)-41.01%
ROE(5y)-37.89%
ROIC(3y)N/A
ROIC(5y)N/A
NGNE Yearly ROA, ROE, ROICNGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

NGNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGNE Yearly Profit, Operating, Gross MarginsNGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, NGNE has more shares outstanding
Compared to 5 years ago, NGNE has more shares outstanding
Compared to 1 year ago, NGNE has an improved debt to assets ratio.
NGNE Yearly Shares OutstandingNGNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
NGNE Yearly Total Debt VS Total AssetsNGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

NGNE has an Altman-Z score of 2.80. This is not the best score and indicates that NGNE is in the grey zone with still only limited risk for bankruptcy at the moment.
NGNE has a Altman-Z score of 2.80. This is in the better half of the industry: NGNE outperforms 73.89% of its industry peers.
NGNE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
NGNE has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.8
ROIC/WACCN/A
WACCN/A
NGNE Yearly LT Debt VS Equity VS FCFNGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

NGNE has a Current Ratio of 9.09. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 9.09, NGNE is in the better half of the industry, outperforming 76.73% of the companies in the same industry.
A Quick Ratio of 9.09 indicates that NGNE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.09, NGNE is doing good in the industry, outperforming 76.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.09
Quick Ratio 9.09
NGNE Yearly Current Assets VS Current LiabilitesNGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

NGNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.51%, which is quite impressive.
EPS 1Y (TTM)67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 0.02% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.2%
EPS Next 2Y10.6%
EPS Next 3Y0.02%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NGNE Yearly Revenue VS EstimatesNGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
NGNE Yearly EPS VS EstimatesNGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NGNE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGNE Price Earnings VS Forward Price EarningsNGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGNE Per share dataNGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.6%
EPS Next 3Y0.02%

More info and screens

0

5. Dividend

5.1 Amount

NGNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROGENE INC

NASDAQ:NGNE (2/21/2025, 8:00:01 PM)

After market: 17.36 0 (0%)

17.36

+0.05 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-18 2024-11-18/amc
Earnings (Next)03-17 2025-03-17/amc
Inst Owners109.15%
Inst Owner Change-96.38%
Ins Owners9.04%
Ins Owner Change5.12%
Market Cap257.80M
Analysts87.69
Price Target53.86 (210.25%)
Short Float %14.97%
Short Ratio7.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.36%
Min EPS beat(2)-1.77%
Max EPS beat(2)4.5%
EPS beat(4)2
Avg EPS beat(4)-2.46%
Min EPS beat(4)-26.17%
Max EPS beat(4)13.62%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.28%
EPS NY rev (1m)0%
EPS NY rev (3m)1.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)102.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 278.7
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 1.88
EV/EBITDA N/A
EPS(TTM)-4.79
EYN/A
EPS(NY)-4.42
Fwd EYN/A
FCF(TTM)-5.63
FCFYN/A
OCF(TTM)-5.6
OCFYN/A
SpS0.06
BVpS9.25
TBVpS9.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.34%
ROE -51.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.38%
ROA(5y)-33.24%
ROE(3y)-41.01%
ROE(5y)-37.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.92%
Cap/Sales 50.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.09
Quick Ratio 9.09
Altman-Z 2.8
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)109.95%
Cap/Depr(5y)173.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190.24%
EPS Next Y22.2%
EPS Next 2Y10.6%
EPS Next 3Y0.02%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-168.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-73.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-77.58%
OCF growth 3YN/A
OCF growth 5YN/A